Bell KJL - Search Results

1

Estimating the magnitude and healthcare costs of melanoma in situ and thin invasive melanoma overdiagnosis in Australia.

Lindsay D, Bell KJL, Olsen CM, Whiteman DC, Pathirana T, Collins LG. Lindsay D, et al. Among authors: bell kjl. Br J Dermatol. 2024 Nov 18;191(6):906-913. doi: 10.1093/bjd/ljae296. Br J Dermatol. 2024. PMID: 39026390

2

Lifetime risk of prostate cancer overdiagnosis in Australia: quantifying the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach.

Pathirana T, Hayen A, Doust J, Glasziou P, Bell K. Pathirana T, et al. BMJ Open. 2019 Mar 10;9(3):e022457. doi: 10.1136/bmjopen-2018-022457. BMJ Open. 2019. PMID: 30858156 Free PMC article.

3

Is the risk of cancer in Australia overstated? The importance of competing mortality for estimating lifetime risk.

Bach AC, Lo KS, Pathirana T, Glasziou PP, Barratt AL, Jones MA, Bell KJ. Bach AC, et al. Med J Aust. 2020 Jan;212(1):17-22. doi: 10.5694/mja2.50376. Epub 2019 Nov 6. Med J Aust. 2020. PMID: 31691294

4

Causal inference in melanoma epidemiology using Mendelian randomization.

Bell KJL. Bell KJL. Br J Dermatol. 2020 Jan;182(1):13-14. doi: 10.1111/bjd.18646. Epub 2019 Nov 28. Br J Dermatol. 2020. PMID: 31782141 No abstract available.

5

Estimating the magnitude of cancer overdiagnosis in Australia.

Glasziou PP, Jones MA, Pathirana T, Barratt AL, Bell KJ. Glasziou PP, et al. Med J Aust. 2020 Mar;212(4):163-168. doi: 10.5694/mja2.50455. Epub 2019 Dec 19. Med J Aust. 2020. PMID: 31858624 Free PMC article.

6

Estimating the potential impact of interventions to reduce over-calling and under-calling of melanoma.

Gibson M, Scolyer RA, Soyer HP, Ferguson P, McGeechan K, Irwig L, Bell KJL. Gibson M, et al. Among authors: bell kjl. J Eur Acad Dermatol Venereol. 2021 Jul;35(7):1519-1527. doi: 10.1111/jdv.17189. Epub 2021 Apr 4. J Eur Acad Dermatol Venereol. 2021. PMID: 33630379

7

Trends in Prostate Specific Antigen (PSA) testing and prostate cancer incidence and mortality in Australia: A critical analysis.

Pathirana T, Sequeira R, Del Mar C, Dickinson JA, Armstrong BK, Bell KJL, Glasziou P. Pathirana T, et al. Among authors: bell kjl. Cancer Epidemiol. 2022 Apr;77:102093. doi: 10.1016/j.canep.2021.102093. Epub 2022 Jan 11. Cancer Epidemiol. 2022. PMID: 35026706

8

Melanoma overdiagnosis: why it matters and what can be done about it.

Bell KJL, Nijsten T. Bell KJL, et al. Br J Dermatol. 2022 Oct;187(4):459-460. doi: 10.1111/bjd.21750. Epub 2022 Aug 5. Br J Dermatol. 2022. PMID: 35929572 Free PMC article.

9

Including Information on Overdiagnosis in Shared Decision Making: A Review of Prostate Cancer Screening Decision Aids.

Pathirana TI, Pickles K, Riikonen JM, Tikkinen KAO, Bell KJL, Glasziou P. Pathirana TI, et al. Among authors: bell kjl. MDM Policy Pract. 2022 Oct 11;7(2):23814683221129875. doi: 10.1177/23814683221129875. eCollection 2022 Jul-Dec. MDM Policy Pract. 2022. PMID: 36247841 Free PMC article.

10

Breast cancer screening from age 40 in the US.

Bell KJ, Nickel B, Pathirana T, Blennerhassett M, Carter S. Bell KJ, et al. BMJ. 2024 Jun 24;385:q1353. doi: 10.1136/bmj.q1353. BMJ. 2024. PMID: 38914429 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

150 results

Search Page

Filters